202 related articles for article (PubMed ID: 21520195)
1. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S
Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195
[TBL] [Abstract][Full Text] [Related]
2. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel.
Griffin S; Stgelais C; Owsianka AM; Patel AH; Rowlands D; Harris M
Hepatology; 2008 Dec; 48(6):1779-90. PubMed ID: 18828153
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus p7: molecular function and importance in hepatitis C virus life cycle and potential antiviral target.
Khaliq S; Jahan S; Hassan S
Liver Int; 2011 May; 31(5):606-17. PubMed ID: 21457434
[TBL] [Abstract][Full Text] [Related]
4. Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C.
Mihm U; Grigorian N; Welsch C; Herrmann E; Kronenberger B; Teuber G; von Wagner M; Hofmann WP; Albrecht M; Lengauer T; Zeuzem S; Sarrazin C
Antivir Ther; 2006; 11(4):507-19. PubMed ID: 16856625
[TBL] [Abstract][Full Text] [Related]
5. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus.
Steinmann E; Whitfield T; Kallis S; Dwek RA; Zitzmann N; Pietschmann T; Bartenschlager R
Hepatology; 2007 Aug; 46(2):330-8. PubMed ID: 17599777
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor Development against p7 Channel in Hepatitis C Virus.
Wei S; Hu X; Du L; Zhao L; Xue H; Liu C; Chou JJ; Zhong J; Tong Y; Wang S; OuYang B
Molecules; 2021 Mar; 26(5):. PubMed ID: 33802584
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
8. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HCV p7 as a therapeutic target.
Griffin S
Curr Opin Investig Drugs; 2010 Feb; 11(2):175-81. PubMed ID: 20112167
[TBL] [Abstract][Full Text] [Related]
10. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production.
Wozniak AL; Griffin S; Rowlands D; Harris M; Yi M; Lemon SM; Weinman SA
PLoS Pathog; 2010 Sep; 6(9):e1001087. PubMed ID: 20824094
[TBL] [Abstract][Full Text] [Related]
11. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels.
Shiryaev VA; Radchenko EV; Palyulin VA; Zefirov NS; Bormotov NI; Serova OA; Shishkina LN; Baimuratov MR; Bormasheva KM; Gruzd YA; Ivleva EA; Leonova MV; Lukashenko AV; Osipov DV; Osyanin VA; Reznikov AN; Shadrikova VA; Sibiryakova AE; Tkachenko IM; Klimochkin YN
Eur J Med Chem; 2018 Oct; 158():214-235. PubMed ID: 30218908
[TBL] [Abstract][Full Text] [Related]
12. Amantadine inhibits the function of an ion channel encoded by GB virus B, but fails to inhibit virus replication.
Premkumar A; Dong X; Haqshenas G; Gage PW; Gowans EJ
Antivir Ther; 2006; 11(3):289-95. PubMed ID: 16759044
[TBL] [Abstract][Full Text] [Related]
13. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
14. A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria.
Griffin SDC; Harvey R; Clarke DS; Barclay WS; Harris M; Rowlands DJ
J Gen Virol; 2004 Feb; 85(Pt 2):451-461. PubMed ID: 14769903
[TBL] [Abstract][Full Text] [Related]
15. Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro.
StGelais C; Foster TL; Verow M; Atkins E; Fishwick CW; Rowlands D; Harris M; Griffin S
J Virol; 2009 Aug; 83(16):7970-81. PubMed ID: 19493992
[TBL] [Abstract][Full Text] [Related]
16. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
17. Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7.
Mandour YM; Breitinger U; Ma C; Wang J; Boeckler FM; Breitinger HG; Zlotos DP
Drug Des Devel Ther; 2018; 12():1019-1031. PubMed ID: 29750015
[TBL] [Abstract][Full Text] [Related]
18. Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression.
Quarato G; Scrima R; Ripoli M; Agriesti F; Moradpour D; Capitanio N; Piccoli C
Biochem Pharmacol; 2014 Jun; 89(4):545-56. PubMed ID: 24726442
[TBL] [Abstract][Full Text] [Related]
19. Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors.
Breitinger U; Farag NS; Ali NKM; Breitinger HA
Biophys J; 2016 Jun; 110(11):2419-2429. PubMed ID: 27276260
[TBL] [Abstract][Full Text] [Related]
20. In depth analysis on the binding sites of adamantane derivatives in HCV (hepatitis C virus) p7 channel based on the NMR structure.
Du QS; Wang SQ; Chen D; Meng JZ; Huang RB
PLoS One; 2014; 9(4):e93613. PubMed ID: 24714586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
